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Background
There is evidence that long-term omalizumab treatment
might have disease-modifying activity, however, important
questions concerning treatment duration after clinical
improvement remain unanswered. This study aimed to
evaluate follow-up of asthma control and quality of life
after discontinuation of omalizumab in severe asthmatic
patients previously treated with long term omalizumab.
Methods
This is a prospective, observational study. Omalizumab
therapy was stopped in 16 severe allergic asthmatic patients
who previously treated with omalizumab over a 3 years
period. Asthma Control Test (ACT), Asthma Quality of
Life Questionnaire (AQLQ), pulmonary function test and
severe exacerbations were recorded for one year at three
month intervals after discontinuation of omalizumab.
Results
The mean age was 53.5±9.5 and duration of asthma was
21.2±11.2 years. Serum total IgE level was 380.3±196
IU/mL. Mean duration of omalizumab treatment was
54.6±15 months. Loss of asthma control was documen-
ted in 10/16 patients (62.5%). The mean time to the
first moderate to severe asthma exacerbation after dis-
continuation was 2.68±2.2 months. No correlation was
found between time to loss of control and duration of
omalizumab treatment. The mean score of ACT in the
time of discontinuation of omalizumab decreased from
22.13±1.2 to 21.06±1.5 at 3th months (p=0.0001) and to
19.3 ±2.0 at 12th months of discontinuation (p=0.005).
The number of exacerbation within the last 12 months
increased from 1.3±0.9 to 3.4±3.2 (p=0.006), and the
number of hospitalization increased from 0.12±0.26 to
0.6±0.9 within 12 months of discontinuation. The mean
score of AQLQ decreased from 4.17±0.8 to 3.26±0.7 at
12th months of discontinuation (p=0.0001).
Conclusions
The discontinuation of omalizumab after the successful
long term therapy was associated of early loss of asthma
control, moderate to severe exacerbation of the disease, and
impaired quality of life. This suggest that the decision
regarding discontinuation of omalizumab treatment should
be undertaken individually after careful evaluation of bene-
fits and risks in severe asthmatic patients eventhough they
had been treated with a long enough course of omalizumab.
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